Bosulif, also known as bosutinib, is a cancer medication primarily used to treat adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or blast crisis, as well as adult patients with Ph+ acute lymphoblastic leukemia (ALL) that has not responded to at least one prior treatment [1].

According to the prescribing information, bosulif is not approved for use in pediatric patients, and the efficacy and safety of bosulif in pediatric patients have not been studied [2]. This suggests that bosulif patients are primarily adults.

The drug's manufacturer, Pfizer, has also stated that bosulif is not approved for children, indicating that the drug is not suitable for pediatric patients [3].

According to DrugPatentWatch.com, bosutinib (bosulif) has lost some of its patent protection, but it is still protected in various countries due to different patents having different expiration dates [4].

Sources:

[1] https://www.accessdata.fda.gov/drugsatfdadocs/label/2013/022384s011lbl.pdf
[2] https://www.accessdata.fda.gov/drugsatfdadocs/label/2013/022384s011lbl.pdf
[3] https://www.pfizer.com/news/important-safety-information
[4] https://www.drugpatentwatch.com/drugs/bosutinib/